Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis

Fig. 2

Incidence of nausea and vomiting. The incidence of nausea (a) and vomiting (b) in the acute phase, delayed phase, and overall treatment period. Black bars denote the CBDCA+PEM group, while white bars indicate the CBDCA+PTX group. The incidence of delayed nausea was significantly higher in the CBDCA+PEM group than that in the CBDCA+PTX group

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us